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Abstract
Protein phosphorylation mediates many critical cellular responses and is essential for many biological functions during
development. About one-third of cellular proteins are phosphorylated, representing the phosphor-proteome, and
phosphorylation can alter a protein’s function, activity, localization and stability. Tyrosine phosphorylation events mediated
by aberrant activation of Receptor Tyrosine Kinase (RTK) pathways have been proven to be involved in the development of
several diseases including cancer. To understand the systems biology of RTK activation, we have developed a phosphor-
proteome focused on tyrosine phosphorylation events under insulin and EGF signaling pathways using the PhosphoScanH
technique coupled with high-throughput mass spectrometry analysis. Comparative proteomic analyses of all these tyrosine
phosphorylation events revealed that around 70% of these pY events are conserved in human orthologs and paralogs. A
careful analysis of published in vivo tyrosine phosphorylation events from literature and patents revealed that around 38%
of pY events from Drosophila proteins conserved on 185 human proteins are confirmed in vivo tyrosine phosphorylation
events. Hence the data are validated partially based on available reports, and the credibility of the remaining 62% of novel
conserved sites that are unpublished so far is very high but requires further follow-up studies. The novel pY events found in
this study that are conserved on human proteins could potentially lead to the discovery of drug targets and biomarkers for
the detection of various cancers and neurodegenerative diseases.
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Introduction
Unraveling signaling networks from the perspective of under-
standing systems biology has been the most popular approach to
set up an effective platform to identify sensitive cell signaling nodes
leading to novel drug targets [1]. High-throughput mass
spectrometry approaches along with improved techniques such
as SILAC for quantitative proteomics have provided the building
blocks of the current knowledge base for this new grammar of drug
discovery [2]. About 60% of Drosophila proteins have human
homologues with well-conserved canonical signaling cascades.
Because Drosophila is a less complex model system than a
vertebrate, it gives an opportunity to analyze complex signaling
networks and translate the findings to identify novel drug targets
for human diseases. Datasets from model systems with conserved
canonical signaling pathways (such as Drosophila) play an
important part in rapidly generating a knowledge base.
Aberrant activation of RTK pathways has been shown to be
involved in the development of various types of cancers [3–6].
Recent therapeutic approaches have involved the development of
drugs in the form of small molecules or monoclonal antibodies that
block or control activation of tyrosine phosphorylation events on
specific proteins to control the progression of cancer; some of these
are available currently in the market [7],[8].
The technically challenging nature of tyrosine phosphorylation
modifications is mainly attributed to: 1) occurrence of tyrosine
phosphorylation modifications on very low-abundance proteins, 2)
lower relative abundance of tyrosine phosphorylations compared
to serine and threonine phosphorylations, 3) very low stoichiom-
etry and 4) labile nature of pY events during various chemical
manipulations as required for mass spectrometry analysis [2].
Unlike serine and threonine phosphorylation modifications, the
rules of consensus do not work well with tyrosine phosphorylation,
and programs based on algorithms to predict tyrosine phosphor-
ylation have not matched experimental outcomes. Hence a
comprehensive high-throughput effort focused on generating
tyrosine phosphorylation profiles will add to the knowledge base
used to construct robust algorithms based on large datasets.
Here we report a phosphor-proteome from Drosophila
exclusively focused on tyrosine phosphorylation events under
insulin and EGF signaling pathways. We also present the salient
features of the Drosophila proteome architecture and the
comparative proteomic analysis for conserved tyrosine phosphor-
ylation events on human proteins.
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Phosphopeptide profiles from Drosophila S2 (EGFR) cells
Using the PhosphoScanH technique [9], a high-throughput
mass spectrometric analysis of lysates after independent stimula-
tion of the cloned human EGF receptor (ErbB1) and the
endogenous insulin-like receptor (InR) in S2 cells yielded a
tyrosine phosphopeptide spectrum of 658 tyrosine phosphorylated
peptides. Out of these 658 phosphopeptides, 511 were non-
redundant consisting of 543 individual tyrosine phosphorylation
(pY) events from 290 different proteins spanning the entire
Drosophila proteome, with 1-14 sites per protein. The time points
of RTK activation (0, 2, 8 and 12 minutes) used for mass
spectrometry analysis represent the dynamics of D-ERK activation
upon RTK stimulation. RTK-mediated activation of D-ERK in
these S2 (EGFR) cells is initiated as early as 2 minutes and
decreases after 12 minutes.
Activation of the endogenous insulin receptor yielded 63
peptides with 70 pY events on 38 different proteins whereas
activation of over-expressed ErbB1 in S2 cells yielded 283
phosphopeptides containing 325 pY events on 177 proteins.
About 20% (116/511) of phosphopeptides containing 146 pY
events on 79 proteins were also found in serum-starved samples
that were devoid of GF treatment (Figure 1).
We found 6 pY events on Drosophila Insulin-like receptor (InR)
out of which three are conserved in the human insulin receptor
and IGF-1R. We identified three phosphorylation sites (Y1110,
Y1172 and Y1192) on the cloned ErbB1 receptor in the S2 cell
line used in this study.
Architecture of RTK-mediated Tyrosine phosphor-
proteome
Classification of phosphoproteins revealed various functional
categories such as kinases, signaling adaptors, actin binders,
microtubule regulators, cell-adhesion molecules, GEFs/GAPs,
ubiquitin modifiers, transcriptional and translational regulators,
intracellular transport factors, endocytotic epsins, molecular
chaperones and proteins involved in various biosynthetic pathways
including carbohydrate metabolism. A detailed classification of
Drosophila tyrosine phosphopeptides into 16 different categories is
given in Table S1 along with information about activated RTK
(InR or ErbB1) corresponding to each peptide.
The phosphopeptide profiles obtained upon activation of insulin
and EGF RTKs gave the largest spectrum of pY events,
representing all major signaling pathways (MAPK pathway,
PI3Kinase pathway, STAT pathway and PLCc pathway) under
RTK activation responsible for cell growth, proliferation, survival
and differentiation.
About one-fourth of the phosphoproteins (74/290) found in this
study have no known molecular or biological function, but about
half of these have motifs suggestive of their molecular function.
In the context of Drosophila development, phosphoproteins
found in this study are involved in early embryogenesis,
cellularization, early and late blastulation, gastrulation, patterning
and cell migration. Proteins involved in major organogenesis
pathways such as heart and muscle development, tubulogenesis
(tracheal and myotube development), dorsal vessel, CNS develop-
ment and reproductive system and down-regulation of RTKs
(receptor endocytosis pathway) are also phosphorylated. A detailed
illustration of various organ systems, cellular processes and
signaling pathways represented by the tyrosine phosphor-
proteome is illustrated in Figure 2.
In the category of RTKs other than insulin and EGFR, the pvr-
(PGDF and VEGF homologue) gene is a major protein with 13 pY
events. Classification of pY events based on cellular biological
processes yielded four major categories: 1) signaling proteins in
CNS development (101 pY events on 44 proteins), 2) dorsal
closure (65 pY events on 11 proteins), 3) cell polarity (29 pY events
on 19 proteins) and 4) Ras-interacting proteins that included REF
and GEFs (22 pY events on 18 proteins).
Comparative analysis of Drosophila phosphoproteome
against human protein database
Using InParanoid (SBC) and HomoloGene (NCBI) browsers
and the eukaryotic ortholog list from Flybase, a search for human
orthologs of Drosophila proteins yielded 216 protein matches. For
those cases in which we could not identify any human ortholog, we
conducted two different BLAST searches (BLAST2 and BLASTP)
to find out the nearest human protein match. ClustalW2 (EMBL-
EBI) analysis of 511 tyrosine phosphopeptides on 290 proteins was
done using human protein databases (Swiss-Prot and NCBI) to
uncover all the pY events conserved in respective human
homologous proteins. The standard parameters (Protein Gap
open penalty: 10.0; Gap Extension penalty: 0.2; Protein matrix:
Gonnet; Protein ENDGAP: -1 and GAPDIST: 4) were used for
the entire analysis. Out of these, 175 human protein matches had
conserved phosphorylated tyrosines. Often a single Drosophila
Figure 1. Classification of RTK-mediated pY proteome based




PLoS ONE | www.plosone.org 2 August 2008 | Volume 3 | Issue 8 | e2877protein match contained more than one human protein with
conserved tyrosine.
About 75.1% (244/325) of pY events upon ErbB1 stimulation
are conserved in the human proteome compared to 65.7% (46/70)
from activation of insulin receptor and 56.8% (83/146) of pY
events common to both EGF and insulin stimulation. A total of
373 pY events (68. 9%) in this data are conserved in the human
proteome (Figure 1).
The human proteins with conserved tyrosines had protein
homology ranging from as high as 95% to as low as 20%. We
found many tyrosines conserved on the human tyrosine kinases,
receptors and a variety of cytoplasmic and membrane-bound
proteins involved in CNS development (especially the process of
axon guidance and retinal degeneration), cell polarity and
carbohydrate metabolism. We checked the various literatures
(PubMed) and databases (PhosphoSiteH) hosted by CST Inc,
UniProtKB/Swiss-Prot (http://www.expasy.org/uniprot) and
PhosphoPep (http://www.phosphopep.org/) to see if the conserved
tyrosines are actual in vivo sites on human proteins. Based on the
available literature, 38% of the hits found in this study are already
found and reported as confirmed in vivo tyrosine phosphorylation
sites in human proteins. Table 1 contains a category-wise count of
conserved pY events that are confirmed in vivo sites in human
proteins as well the novel sites that are not reported so far.
Figure 2. Overall comparative proteomic analysis of Drosophila and human proteomes. (a) analysis shows a total of 541 pY events, of
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than one human protein with equivalent molecular function even
if they are distantly related, irrespective of the extent of protein
homology. For example, the tyrosines Y1545 and Y1550 on
Drosophila insulin receptor (InR) are conserved in human INR,
IGF-1R RET oncogene, LTK, MUSK, ALK (anaplastic lympho-
ma kinase), ALK Ki-1 variant, TFG/ALK fusion kinase, NTRK2,
NTRK2 and MERTK. From the same perspective we find a
conserved pY event on the Ras interacting protein coded by
roughened (R) which is conserved in H-Ras, K-Ras R-Ras, N-Ras,
RAP1A and RAP1B. A detailed clustal map showing the clustal
alignment of Gene R with human proteins showing conserved
tyrosines is given in Figure 3.
Many signaling proteins with conserved tyrosines are
involved in disease phenotypes
Tyrosine phosphorylation events conserved on proteins involved
in muscular dystrophy, retinal degeneration, Alzheimer’s, breast
cancers, acute myelogenous leukemia (AML), aggressive melano-
mas and several other diseases are very interesting molecular
targets warranting further validation in transgenic mouse models
and tumor cell lines. In total we find 30 pY events on 25 proteins
involved in various types of cancers, 8 pY events on 8 leukemia
related proteins, 34 pY events on 30 proteins involved in various
genetic disorders, and 18 pY events on 14 proteins involved in
various neurodegenerative diseases. A list of important proteins
involved in human disease development with the location of
conserved pY residues is given in Table 2 and a detailed list of all
the human proteins with conserved tyrosines that are phosphor-
ylated in respective Drosohila proteins is given in Tables S2 and
S3. A few of these conserved pY events are specific to a particular
isoform of the respective protein orthologs. A small number of pY
events on fly proteins reveal natural (Y-F, Y-H, Y-W and Y-D)
substitutions in the respective human orthologs (Table S2).
Discussion
The tyrosine phosphopeptide profiles presented here represent
the largest dataset reported in Drosophila to date. This dataset is
unique because it highlights activated proteins upon activation of
growth factor RTKs (endogenous insulin RTK and human EGFR).
Many of the novel phosphorylation events found in this study on
Table 1. Summary of proportion of tyrosine phosphorylation sites in Drosophila RTK proteome based on molecular functional
categories.
Major
Group Molecular Classification Fly specific
Conserved pY events reported in
literature to date
Conserved novel pY events not
yet reported
# of pY events # of proteins # of pY events # of proteins
1 Cytoplasmic tyrosine kinases 12 10 7 8 5
2 Receptor Tyrosine kinases 7 7 3 11 4
3 Cytplasmic S/T kinases 4 12 11 4 4
4 Receptor S/T kinases - 3 2 3 2
5 Other kinases 9 1 1 7 4
6 Other receptors 13 15 10 26 13
7 Ligands for RTKs 1 - - - -
8a Signaling adaptor proteins 9 16 11 8 7
8b Actin binding proteins 16 14 5 10 7
8c Other proteins in cytoskeleton 5 4 3 6 4
8d Cell adhesion proteins - 1 1 5 4
9 Ras interacting proteins 8 6 5 11 11
10 Proteases 5 3 3 10 8
11a Cation transporters - 1 1 6 7
11b Signaling related transporters (ABC family) 1 3 3 4 3
11c Vesicle mediated transporters 3 4 4 4 4
11d Oligopeptide transporters 3 - - - -
11e Nucleotide transporters 1 - - 2 1
12 Carbohydrate metabolism related transporters 7 3 3 10 7
13 Ion channel proteins 4 - - 2 2
14 Molecular chaperones - 2 2 1 1
15 Transcription related 3 1 1 5 4
16 Translation related 2 4 4 7 6
17 Other signaling proteins 14 7 6 27 17
18 Proteins with known motifs & unknown functions 13 11 9 21 22
19 Proteins with unknown motifs & functions 28 15 5 32 28
Total 168 143 100 230 175
doi:10.1371/journal.pone.0002877.t001
Drosophila pY Proteome
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represent new signaling nodes that merit further validation.
One of the major issues in the conventional SDS-PAGE method
to identify pY modifications is the significant loss during recovery
of peptides after in-gel digestion of total protein entrapped in the
PAGE gel matrix. Even though this is not an issue in the case of
protein identification as such, it may pose many technical
impediments for identifying post-translational modifications,
especially on tyrosine (pY), which are labile during chemical
processing of peptides and recovery from the gel matrix. The
PhosphoScanH technique is a non-gel based method involving
direct immunoaffinity precipitation of pY peptides concentrated
from whole-cell-lysate digests; it facilitates identification of pY sites
on both less-abundant proteins and proteins of low stoichiometry
of phosphorylation, and importantly, avoids technical complica-
tions of peptide recovery from gel matrix. The quality and
quantity of phosphopeptides obtained in this study is far better
than methods using various IMAC columns. Evaluating various
enrichment techniques for tyrosine identification of tyrosine
phosphorylations, Schumacher et al [10] found that immunoaffi-
nity precipitation is superior to the immunoaffinity chromatogra-
phy method.
Peptides containing multiple acidic residues (D and E) around
phosphorylated tyrosines are technically difficult for mass
spectrometric analysis. Very low stoichiometry of tyrosine
phosphorylation makes it almost impossible to detect many
tyrosine modifications on low-abundance proteins. A typical
example in our case was the identification of tyrosine phosphor-
ylation sites on a nuclear import protein (Dim7) with a very low
stoichiometry (0.004 moles/mole). High cell quantities (2610
9
cells) used in conventional SDS-PAGE methods failed to identify
any pY sites on this protein. But using the PhosphoScanH
technique, we identified two pY sites on this protein, with just
1610
8 cells [S. Krishnamoorthy and L.A. Perkins, unpublished].
Figure 3. Tyrosine phosphorylation in Roughened (Gene R) from Drosophila is conserved in human H-RAS, K-RAS, N-RAS and R-
RAS. The Drosophila protein sequence (blue with the phosphorylated tyrosine in red) aligns with several human protein sequences (black). The
conserved tyrosines in the human proteins are highlighted in green.
doi:10.1371/journal.pone.0002877.g003
Drosophila pY Proteome
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HT screens
A minimal overlap of pY sites from Kc cell proteome data is
seen with respect to tyrosine phosphorylation [11]. A considerable
overlap of proteins representing various phosphopeptides from our
HT mass spectrometry data from insulin stimulation was seen with
the candidate gene list from RNAi screen data for insulin RTK
mediated ERK activation [12]. But the EGF RTK mediated HeLa
cell phosphor-proteome data showed overlap of only one pY site
with respect to tyrosine phosphorylation modifications, even
though many candidate proteins with conserved tyrosines from
our data are either serine or threonine phosphorylated upon
EGFR activation [2]. A recent report [13] on signaling networks
assembled by oncogenic EGFR and c-Met pathways and a HT
mass spectrometry analysis of pervanadate-stimulated S2 cells [14]
data have a considerable overlap with our data.
The RTK mediated tyrosine phosphor-proteome network
under insulin and EGF RTKs has not only validated existing
tyrosine phosphorylated signaling nodes but also reveals several
novel insights in to regulation of RTK signaling and crosstalk with
various other pathways (Figures 4a and 4b).
Translational value of conserved pY events in Drosophila
proteome and future directions
The novel tyrosine phosphorylation events from the Drosophila
proteome conserved in 100 human orthologs and paralogs
constitute a valuable resource to translate the missing signaling
connections and nodal points in the human proteome from the
perspective of disease development. The data warrants further
validation in human tumor cell lines and tissue samples to see if
these pY events are up-regulated or down-regulated in GF
signaling with respect to human disease phenotypes.
Recent reports indicate the importance of genes in glycolytic
pathways in cancer progression [15]. Mechanisms of tumor growth
based on the selective switching of cellular processes towards
anabolic pathways rather than oxidative phosphorylation also stress
the importance of glycolytic proteins in cancer development [16].
Our study in the fly proteome reveals that several proteins involved
Table 2. Selected list of important human proteins with conserved fly yrosine phosphorylation involved in disease phenotypes.
Protein with
putative pY event Accession # Location of pY Disease
ABCG1:Y84 P45844 Cytoplasmic domain Over-expressed in patients with Tangier disease
ABCG2:Y44 Q9UNQ0 unknown Up-regulated in brain tumors.
ADAMTS20:Y 1572 P59510 TSP type-1 13 Over-expressed in several brain, colon and breast carcinomas.
ATP1A3:Y532 P13637 Cytoplasmic domain Defects in ATP1A3 are the cause of dystonia-12 (DYT12)
BIRC6:Y4102, Y4130 Q9NR09 unknown Expressed in brain cancer cells.
CACNA1F:Y1769 O60840 Cytoplasmic domain Congenital stationary night blindness type 2 (CSNB2)
DMD-Dp140bc:Y934 NP_004014 unknown DMD are the cause of Duchenne muscular dystrophy (DMD), Becker
muscular dystrophy (BMD), X-linked dilated cardiomyopathy (XLCM)
ETV6:Y391 P41212 ETS domain Various leukemias like AML, CMML, ALL, MDS etc.
Fibulin6:Y5045; Y5296 Q96RW7 Nidogen G2 beta-barrel domain Age-related macular degeneration type 1 (ARMD1)
GAS7:Y31 O60861 WW domain A chromosomal aberration involving GAS7 is a cause of acute myeloid
leukemia
HMCN1:Y 2861 Q96RW7 Ig-like C2-type 26 between
C2-type 28
Defects in HMCN1 are a cause of age-related macular degeneration type 1
(ARMD1)
HMCN1:Y3053
INVS:Y566 Q9Y283 IQ 1 domain Defects in INVS are the cause of nephronophthisis 2 (NPHP2)-Infant kidney
disease
MXRA5:Y2709 Q9NR99 Ig-like C2-type 11 Expressed in arthritic tissues, Over-expressed in centenarians. Expression is
reduced from young to old but increased from old to centenarians.
MXRA5:Y2717
PROM1:Y828 O43490 Cytoplasmic domain Defects in PROM1 are the cause of an autosomal recessive form of retinal
degeneration.
HRAS:Y157 P01112 Unknown Mutated in various cancers
KRAS:Y157 P01116 Unknown
NRAS:Y157 P01111 unknown
REG1A:Y48 P05451 C-type lectin domain on
lithostathine 1 alpha chain
Alzheimer disease and Down syndrome patients show enhanced
accumulation of PSP-like proteins in their brains
REG1A:Y49
SPAST:Y149 Q9UBP0 MIT domain Defects in SPAST are the cause of spastic paraplegia type 4 (SPG4)
TNKS2:Y569 Q9H2K2 ANK 11 repeat Highly expressed in mammary gland, breast and breast carcinoma
UNC5C:Y449 O95185 Cytoplasmic domain Down-regulated in multiple cancers including colorectal, breast, ovary,
uterus, stomach, lung, or kidney cancers
VEGFR3:1063 P35916 Cytoplasmic domain Juvenile hemangioma
doi:10.1371/journal.pone.0002877.t002
Drosophila pY Proteome
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candidate human proteins with conserved tyrosine residues merit
further study. Upregulation of monocarboxylic transporters (MCA)
in Type-1 diabetic patients indicate the possibility of increased
capacity of the brain to use non-glucose substrates to meet energy
requirements during hypoglycemia [17]. Our study reveals that
several MCA transporters are tyrosine phosphorylated upon RTK
activation. It will be interesting to see if the human orthologs with
conserved phosphorylated tyrosines found in this study are involved
in similar mechanisms in brain-cell energetics.
Based on the available protein expression data, interesting
candidate proteins could be selected for analysis of the dynamics of
tyrosine phosphorylation with respect to disease development.
Reverse-phase protein microarrays could be a very useful tool in
this direction [18]. Peptide arrays containing novel conserved pY
modifications could be used to probe SH2 domain containing




S2 cells stably transfected with human ErbB1 (gift from David
Baker, Leiden University Medical Center, Netherlands) were
maintained in Schneider’s Drosophila medium (CAMBREX Inc.)
supplemented with 10% fetal bovine serum (Mediatech, Inc.),
penicillin and streptomycin.
Growth factor stimulation
S2 (EGFR) cells were grown in 15-cm culture dishes to about 80%
confluency. The cells were starved by replacing complete medium
with minimal medium without serum (15mL of minimal medium per
plate) for about 18–20 hours. The next day cells were stimulated with
EGF (100ng/mLof medium) or insulin (5 ug/mLof medium) for 2, 8
and 12 minute time intervals. A total of 10 plates that gave
approximately 2610
8 cells were used per stimulation. A set of 10
plates of overnight-starved cells was used as the control. The cells
were lysed after stipulated time of growth factor treatment using the
lysis buffer for containing 6M urea. As per the manufacturer’s
directions,10 mLoflysisbufferwere used tolyse cellsfroma batchof
ten 15-cm culture plates. The lysate from insulin and EGF treated
samples were subjected to further processing as per the manufactur-
er’s directions (PhosphoScanH Kit (P-Tyr-100) #7900, Cell Signaling
Technology Inc., Danvers MA USA).
Peptide extraction, LC-MS/MS analysis and assignment of
tyrosine phosphorylation
Digestion of total lysate with trypsin, reverse phase solid phase
extraction of digests, immunoaffinity purification of phosphopeptides,
Figure 4. Tyrosine phosphorylation signaling pathways in Drosophila. a) Insulin RTK mediated tyrosine signaling pathways. b) EGF RTK
mediated tyrosine phosphorylation signaling pathways.
doi:10.1371/journal.pone.0002877.g004
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MS/MS spectra using Sequest browser and assigning phosphopep-
tide sequences and review of assigned peptide sequences using a two
step process were done at the Cell Signaling Technology facility
following the methods described by Rush et al [9].
Identification of human homologues and conserved
tyrosines on human proteins
A combined list of human orthologs and paralogs for the
respective Drosophila proteins was obtained using InParanoid
(Version 6.0) hosted by SBC, HomoloGene hosted by NCBI and
also using the eukaryotic ortholog list from Flybase.
Two different Blast searches (BLASTP hosted by NCBI and
BLAST2 hosted by SIB blast network) were also made for
individual whole protein sequence of tyrosine phosphorylated
Drosophila proteins against the human protein database.
ClustalW2, a multiple sequence alignment program was used to
align each Drosophila protein sequence against all the human
protein matches from the blast searches to identify all the
conserved tyrosines that are tyrosine phosphorylated in each of
the 290 Drosophila proteins. The parameters used were: Protein
Gap open penalty: 10.0; Gap Extension penalty: 0.2; Protein
matrix: Gonnet; Protein ENDGAP: -1 and GAPDIST: 4.
Supporting Information
Table S1 Overall classification of tyrosine phosphopeptides
based on functional category of proteins. Summary of all the
tyrosine phosphorylation sites that are specific to insulin RTK,
EGF RTK and sites common to starved control cells/insulin/EGF
treated cells. The conserved position of tyrosine on respective
human ortholog and paralog are given for each phosphorylated
site on Drosophila proteins. The Swiss-Prot protein ID for each
human ortholog and paralog is also provided.
Found at: doi:10.1371/journal.pone.0002877.s001 (0.58 MB
XLS)
Table S2 Human orthologs and paralogs with conserved Y
residues that are phosphorylated in Drosophila proteins. Summary
of all the conserved tyrosines on human proteins. The details of
each conserved tyrosine which includes the protein domain of
tyrosine location, function, subcellular location, tissue specificity
and information on disease phenotypes are given.
Found at: doi:10.1371/journal.pone.0002877.s002 (0.36 MB
XLS)
Table S3 Conserved phosphorylation sites on human proteins
involved in various diseaeses. Summary of the list of putative
tyrosine phosphorylation sites on various human proteins that are
involved in the development of various cancers, leukemias,
neurodegenerative diseases and various genetic syndromes/
disorders.
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